LynxBio is at the forefront of a data-first paradigm shift in drug discovery, leveraging our proprietary patient-based ex vivo disease biology platform. The advent of single-cell and spatial technologies has illuminated the complexity and highly networked nature of biology. Our platform is engineered to decode the intricacies of this complexity, delivering transformative, data-centric (versus hypothesis-driven) insights that blend biotechnology with technology and accelerate the development of groundbreaking therapies from discovery to bedside.

​

Our approach is characterized by its precision in capturing the dynamic interactions of tumor cells within the multifaceted immune environment. By integrating dynamic, functional data with orthogonal multi-omic profiles, we construct a holistic systems-level understanding of human biology. This fusion of diverse data from sophisticated primary patient models enables us to quickly identify and confirm a robust set of druggable targets, enhancing translatability to the clinic.

​

To date, we have formed several strategic partnerships with leading biopharmaceutical companies, underscoring the industry's recognition of our platform's potential. In tandem with these alliances, we are advancing an internal pipeline centered on novel signaling pathways that orchestrate the interplay between immune cells, cancer cells, and the tumor microenvironment. Surpassing traditional drug discovery methods, our approach reveals new facets of biological intricacy and propels the next wave of therapeutic advancements.